¼¼°èÀÇ ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå : ¹é½Å À¯Çüº°, Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2024-2032³â)
Vaccine Contract Manufacturing Market, By Vaccine Type, By Product Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514977
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 265 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 29¾ï 10¸¸ ´Þ·¯°¡ µÇ¾î, 2024-2032³â¿¡ °ÉÃÄ CAGR 8.00%·Î È®´ë

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¹é½Å ¼ö¿ä Áõ°¡¿Í ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö »ê¾÷ÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ Àü¸Á

¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ È®´ë, Àü¿°º´ÀÇ À¯Çà Áõ°¡, ½ÅÈï º´¿øÃ¼¿Í ½Î¿ì´Â »õ·Î¿î ¹é½ÅÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹é½Å¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä°¡ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä¿¡ µû¶ó Á¦¾àȸ»ç´Â È¿À²ÀûÀ¸·Î »ý»ê±Ô¸ð¸¦ È®´ëÇϱâ À§ÇØ Á¦Á¶À§Å¹Ã³¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¹é½Å Á¦Á¶¿¡´Â Á¾Á¾ Ư¼ö ½Ã¼³, ±â¼ú ¹× Àü¹® Áö½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹é½Å Á¦Á¶¿¡ Á¤ÆòÀÌ ÀÖ´Â ¼öŹ Á¦Á¶¾÷ÀÚ´Â È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¦¾àȸ»ç´Â ¿¬±¸°³¹ß¡¤ÆÇ¸Å¿¡ Àü³äÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿¬±¸¿Í ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¹é½Å Á¦Á¶´Â FDA¿Í EMA¸¦ Æ÷ÇÔÇÑ Àü ¼¼°è º¸°Ç ´ç±¹¿¡ ÀÇÇØ °íµµ·Î ±ÔÁ¦µË´Ï´Ù. ±ÔÁ¤ Áؼö Àü¹® Áö½ÄÀ» ¼ö¸³ÇÑ ¼öŹ Á¦Á¶¾÷ü´Â ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­Çϰí ǰÁú ±âÁØ Áؼö¸¦ º¸ÀåÇÔÀ¸·Î½á ½Å±Ô ¹é½Å ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¹Àº Á¦¾à ȸ»ç´Â »ç³» Á¦Á¶ ´É·ÂÀÇ ÇѰ迡 Á÷¸éÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼öŹ Á¦Á¶¾÷ü´Â º¯È­ÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇÏ°í ¼¼°è¿¡ ¹é½ÅÀ» °ø±ÞÇϱâ À§ÇÑ Ãß°¡ ´É·Â, À¯¿¬¼º ¹× È®À强À» ¼³¸íÇÕ´Ï´Ù. µû¶ó¼­ »ý»ê ´É·ÂÀ» °­È­Çϱâ À§ÇØ ¹é½Å ¼öŹ Á¦Á¶´Â ¼ö¿ä º¯È­¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇϰí ÀÖ½À´Ï´Ù.

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 8.00%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹é½Å À¯Çüº° ¼¼ºÐÈ­¿¡ µû¸£¸é, ¹ÙÀÌ·¯½º¼º ÁúȯÀÇ ³ôÀº À¯ÇàÀ¸·Î ÀÎÇØ ¾àµ¶¼º ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â 1°¡ ¹é½ÅÀÇ ºñÀ²ÀÌ ³ô±â ¶§¹®¿¡ 2023³â¿¡´Â 1°¡ ¹é½Å ½ÃÀåÀÌ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº° ºÎ¹®¿¡¼­´Â Àΰ£ °£ÀÇ ¹é½ÅÁ¢Á¾ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àΰ£¿ë ºÎ¹®ÀÌ 2023³âÀÇ ÁÖ¿ä ¿ëµµ¿´½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ ºÎ¹®º°·Î Á¦¾à ȸ»ç ºÎ¹®Àº 2023³â ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ¿´½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ¸·Î, ÀÌ´Â ½ÃÀå »óÀ§ ±â¾÷ÀÇ Á¸Àç ¶§¹®ÀÔ´Ï´Ù.

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀåÀº ¹é½Å À¯Çü, Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

¹é½ÅÀº ¾àµ¶ ¹é½Å, ºÒȰ¼ºÈ­ ¹é½Å, DNA ±â¹Ý ¹é½Å, Åå¼ÒÀÌµå ±â¹ÝÀÇ 4À¯ÇüÀ¸·Î ºÐ·ùµË´Ï´Ù. ¾àµ¶ ¹é½Å ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ¾àµ¶ ¹é½Å ¼ö¿ä¸¦ ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó ´Üµ¶ ¹é½Å°ú È¥ÇÕ ¹é½ÅÀ¸·Î ºÐ·ùµË´Ï´Ù. ´ÜÀÏ ¹é½ÅÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È È¥ÇÕ ¹é½ÅÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó Àΰ£¿ë°ú µ¿¹°¿ëÀ¸·Î ºÐ·ùµË´Ï´Ù. Àΰ£ ºÎ¹®Àº ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù. ¹ÙÀÌ·¯½º¼º Áúȯ°ú ½É°¢ÇÑ Áúº´ÀÇ ¿¹¹æ ¹× ¿¹¹æ ¸é¿ªÀ» ¸ñÇ¥·Î ÇÑ Àΰ£¿¡°Ô ¿¹¹æ Á¢Á¾ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶óÀÌ ºÎ¹® ¼ö¿ä°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î ¹ÙÀÌ¿À Á¦¾à ȸ»ç, ¿¬±¸¼Ò ¹× ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰ ±â¾÷¿¡¼­ ¹é½ÅÀÇ ¿ä±¸¿Í »ý»ê ¼ö Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - Áö¿ªº° ÀλçÀÌÆ®

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ÆÛÁ® ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Á¦Á¶ºñ¿ë Àú°¨, ¹ÙÀÌ¿ÀÀǾàǰ»ê¾÷ÀÇ ¼ºÀå, ÀÇ·áÀÎÇÁ¶ó ÅõÀÚ Áõ°¡ µîÀ» ¹è°æÀ¸·Î ¹é½Å ¼öŹÁ¦Á¶°¡ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Àεµ³ª Áß±¹°ú °°Àº ±¹°¡µéÀº ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶¿Í ´ë±Ô¸ð »ý»ê ´É·ÂÀÇ °æÀï ¿ìÀ§¸¦ Á¦°øÇÏ¿© ¼¼°è ¹é½Å °ø±Þ¸ÁÀÇ Áß¿äÇÑ ÁøÃâ±â¾÷ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - °æÀï ±¸µµ:

¹é½Å ¼öŹ Á¦Á¶ ½ÃÀåÀº ¼Ò¼öÀÇ ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ ¾ö°ÝÇÑ °æÀïÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº Lonza, Catalent, Samsung Biologics µîÀÇ À¯¸íÇÑ ¼öŹ Á¦Á¶ ±â¾÷(CMO)ÀÔ´Ï´Ù. ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå¿¡¼­ ÀÌ·¯ÇÑ ±â¾÷µéÀº ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »ý»ê ´É·ÂÀ» Áö¼ÓÀûÀ¸·Î È®´ëÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ¹é½Å »ý»ê È¿À²°ú ¼öÀ²À» Çâ»ó½Ã۱â À§ÇØ Ã·´Ü »ý¸í °øÇÐ Ç÷§Æû ¹× Á¦Á¶ ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹é½Å ¼öŹ Á¦Á¶ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¹é½Å ¼öŹ Á¦Á¶ ¾÷°èÀÇ Á¶»ç

Á¦5Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå »óȲ

Á¦7Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå-¹é½Å À¯Çüº°

Á¦8Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå-Á¦Ç° À¯Çüº°

Á¦9Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå-¿ëµµº°

Á¦10Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ¹é½Å ¼öŹ Á¦Á¶ ½ÃÀå-Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¹é½Å ¼öŹ Á¦Á¶ ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Vaccine Contract Manufacturing Market size was valued at USD 2,900.10 Million in 2023, expanding at a CAGR of 8.00% from 2024 to 2032.

The practice of a pharmaceutical firm (the contract manufacturer) producing vaccines for another corporation, or the client is known as vaccine contract manufacturing. Through this agreement, the customer can create vaccines under their specifications and needs by utilizing the contract manufacturer's manufacturing experience, facilities, and capabilities.

Vaccine Contract Manufacturing Market- Market Dynamics

Rising demand for vaccines and the biotechnology industry are expected to propel market demand

The global demand for vaccines continues to rise due to expanding vaccination programs, increasing the prevalence of infectious diseases, and the need for new vaccines to combat emerging pathogens. This demand drives pharmaceutical companies to seek contract manufacturing partners to scale up production efficiently. Vaccine manufacturing often requires specialized facilities, technologies, and expertise. Contract manufacturers with established capabilities in vaccine production can offer efficient solutions, enabling pharmaceutical companies to focus on research, development, and distribution. Thus, advancement in research and technology is playing a vital role in market growth.

Vaccine manufacturing is highly regulated by health authorities worldwide including FDA, and EMA. Contract manufacturers with established regulatory compliance expertise can expedite the approval process and ensure adherence to quality standards, reducing time to market for new vaccines. Many pharmaceutical companies may face limitations in their internal manufacturing capacities. Contract manufacturers provide additional capacity, flexibility, and scalability to meet fluctuating demand and supply vaccines globally. Therefore, to enhance manufacturing capabilities, vaccine contract manufacturing complements the market growth with changing demands.

Vaccine Contract Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.00% over the forecast period (2024-2032)

Based on Vaccine Type segmentation, the attenuated segment was predicted to show maximum market share in the year 2023, owing to the high prevalence of viral illness.

Based on Product Type segmentation, the single vaccine segment was predicted to show maximum market share in the year 2023, owing to high monovalent vaccine types.

Based on Application segmentation, the human use segment was the leading Application in 2023, owing to the rising demand for vaccination among humans.

Based on End User segmentation, pharmaceutical companies' segment was the leading End User in 2023, owing to a high number of ongoing developments in pharma companies for vaccine manufacturing.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of top market players.

Vaccine Contract Manufacturing Market- Segmentation Analysis:

The Global Vaccine Contract Manufacturing Market is segmented on the basis of Vaccine Type, Product Type, Application, End User, and Region.

The market is divided into four categories based on Vaccine Type: attenuated, inactivated, DNA-based, and toxoid-based. The attenuated vaccine segment dominates the market. High demand for viral infections is boosting the demand for attenuated vaccines.

The market is divided into two categories based on Product Type: single vaccine and combination vaccine. The single vaccine segment dominates the market. Combination vaccine is anticipated to grow at the highest rate during the forecast period.

The market is divided into two categories based on the Application: human use and veterinary. The human use segment dominates the market. The rising need for vaccination in human beings to avoid and pre-immune against viral & severe diseases is augmenting segment demand.

The market is divided into three categories based on End User: biopharmaceutical companies, research laboratories, and others. The biopharmaceutical companies segment dominates the market and is expected to maintain its high dominance during the forecast period. Increasing number of vaccines need & manufacturing at biopharma companies is fueling market growth.

Vaccine Contract Manufacturing Market- Geographical Insights

Worldwide, the Vaccine Contract Manufacturing market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The Asia-Pacific region is witnessing rapid growth in vaccine contract manufacturing, driven by lower production costs, growing biopharmaceutical industry, and increasing investments in healthcare infrastructure. Countries like India and China are becoming key players in global vaccine supply chains, offering competitive advantages in cost-effective manufacturing and large-scale production capabilities.

Vaccine Contract Manufacturing Market- Competitive Landscape:

The market for Vaccine Contract Manufacturing is characterized by stiff competition among few key companies. Several prominent contract manufacturing organizations (CMOs) dominate the market include Lonza, Catalent, Samsung Biologics, etc. These players in the vaccine contract manufacturing market are continuously expanding their production capacities to meet increasing demand. Companies are investing in advanced biotechnological platforms and manufacturing technologies to improve vaccine production efficiency and yield.

Recent Developments:

In October 2023, Vaxcyte and Lonza Group collaborated for global commercial manufacturing of broad-spectrum Pneumococcal Conjugate Vaccines (PCVs).

In December 2023, Ajinomoto Co., Inc. bought All Forge Biologics Holdings, LLC shares. The facility was targeted to boost production abilities for manufacturing biologics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET KEY PLAYERS

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Vaccine Contract Manufacturing Market Overview

2. Executive Summary

3. Vaccine Contract Manufacturing Key Market Trends

4. Vaccine Contract Manufacturing Industry Study

5. Vaccine Contract Manufacturing Market: COVID-19 Impact Analysis

6. Vaccine Contract Manufacturing Market Landscape

7. Vaccine Contract Manufacturing Market - By Vaccine Type

8. Vaccine Contract Manufacturing Market - By Product Type

9. Vaccine Contract Manufacturing Market - By Application

10. Vaccine Contract Manufacturing Market - By End User

11. Vaccine Contract Manufacturing Market- By Geography

12. Key Vendor Analysis- Vaccine Contract Manufacturing Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â